Published in Cytometry A on November 01, 2008
Flow cytometric analysis of circulating microparticles in plasma. Cytometry A (2010) 2.09
CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. Blood (2010) 1.77
Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol (2009) 1.59
Enhanced cellular uptake of albumin-based lyophilisomes when functionalized with cell-penetrating peptide TAT in HeLa cells. PLoS One (2014) 1.48
Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury. Blood (2015) 1.46
Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation. J Immunol Methods (2010) 1.35
Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat Commun (2015) 1.13
High throughput T epitope mapping and vaccine development. J Biomed Biotechnol (2010) 1.04
A new model for the estimation of cell proliferation dynamics using CFSE data. J Immunol Methods (2011) 0.95
Antigen specific killing assay using CFSE labeled target cells. J Vis Exp (2010) 0.93
Development of a pHrodo-based assay for the assessment of in vitro and in vivo erythrophagocytosis during experimental trypanosomosis. PLoS Negl Trop Dis (2015) 0.88
Tracking immune cell proliferation and cytotoxic potential using flow cytometry. Methods Mol Biol (2011) 0.88
Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes. J Vis Exp (2012) 0.81
Advances in the study of HLA-restricted epitope vaccines. Hum Vaccin Immunother (2013) 0.81
Peptide-based vaccinology: experimental and computational approaches to target hypervariable viruses through the fine characterization of protective epitopes recognized by monoclonal antibodies and the identification of T-cell-activating peptides. Clin Dev Immunol (2013) 0.80
Measuring antigen-specific immune responses, 2008 update. Cytometry A (2008) 0.80
Polyplex exposure inhibits cell cycle, increases inflammatory response, and can cause protein expression without cell division. Mol Pharm (2013) 0.79
ROS produced by NOX2 control in vitro development of cerebellar granule neurons development. ASN Neuro (2015) 0.79
Quantifying CFSE Label Decay in Flow Cytometry Data. Appl Math Lett (2013) 0.78
Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients. J Viral Hepat (2014) 0.78
Effect of nickel chloride on cell proliferation. Open Dent J (2012) 0.77
Designing 3D Mesenchymal Stem Cell Sheets Merging Magnetic and Fluorescent Features: When Cell Sheet Technology Meets Image-Guided Cell Therapy. Theranostics (2016) 0.77
Mathematical models for CFSE labelled lymphocyte dynamics: asymmetry and time-lag in division. J Math Biol (2013) 0.77
A novel statistical analysis and interpretation of flow cytometry data. J Biol Dyn (2013) 0.77
SH2D2A modulates T cell mediated protection to a B cell derived tumor in transgenic mice. PLoS One (2012) 0.76
Elimination of allogeneic multipotent stromal cells by host macrophages in different models of regeneration. Int J Clin Exp Pathol (2015) 0.75
In Vivo Assessment of Stem Cells for Treating Neurodegenerative Disease: Current Approaches and Future Prospects. Stem Cells Int (2017) 0.75
Evaluation of persistence and distribution of intra-dermally administered PKH26 labelled goat bone marrow derived mesenchymal stem cells in cutaneous wound healing model. Cytotechnology (2017) 0.75
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol (2009) 2.32
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma. J Clin Oncol (2007) 2.19
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 2.11
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol (2002) 1.60
Interferon alfa-2a for melanoma metastases. Lancet (2002) 1.55
A pooled analysis of melanocytic nevus phenotype and the risk of cutaneous melanoma at different latitudes. Int J Cancer (2009) 1.51
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Effect of platelet-rich plasma on bone growth and osseointegration in human maxillary sinus grafts: three bilateral case reports. Int J Periodontics Restorative Dent (2002) 1.47
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol (2014) 1.45
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology (2013) 1.44
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood (2008) 1.43
Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother (2011) 1.41
Pigmentary characteristics and moles in relation to melanoma risk. Int J Cancer (2005) 1.40
Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer (2011) 1.26
Expressive disclosure and health outcomes in a prostate cancer population. Int J Psychiatry Med (2002) 1.17
Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res (2009) 1.13
Exposure to sunlamps, tanning beds, and melanoma risk. Cancer Causes Control (2008) 1.11
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850). Clin Cancer Res (2006) 1.10
Cell tracking 2007: a proliferation of probes and applications. Immunol Invest (2007) 1.09
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res (2007) 1.07
Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro Oncol (2011) 1.07
Letter to the Editor Re: Kim, Nowzari, and Rich (2013). Clin Implant Dent Relat Res (2014) 1.06
Use of cell-tracking dyes to determine proliferation precursor frequencies of antigen-specific T cells. Methods Mol Biol (2004) 1.05
An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer (2013) 1.05
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer (2006) 1.05
A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin Cancer Res (2010) 1.05
VISTA is an immune checkpoint molecule for human T cells. Cancer Res (2014) 1.03
Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma. J Clin Invest (2011) 1.03
A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J Immunother (2011) 1.02
Multiple primary melanoma: two-year results from a population-based study. Arch Dermatol (2006) 1.00
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived? Br J Clin Pharmacol (2008) 0.99
Clinical electron paramagnetic resonance (EPR) oximetry using India ink. Adv Exp Med Biol (2010) 0.98
Immunotherapy for the treatment of glioblastoma. Cancer J (2012) 0.93
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res (2007) 0.93
Repair of large sinus membrane perforations using stabilized collagen barrier membranes: surgical techniques with histologic and radiographic evidence of success. Int J Periodontics Restorative Dent (2008) 0.92
Histologic and histomorphometric evaluation of an allograft stem cell-based matrix sinus augmentation procedure. Int J Oral Maxillofac Implants (2011) 0.92
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer. J Clin Oncol (2006) 0.92
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study. Cancer (2008) 0.92
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology (2010) 0.91
Histomorphometric comparison of a biphasic bone ceramic to anorganic bovine bone for sinus augmentation: 6- to 8-month postsurgical assessment of vital bone formation. A pilot study. Int J Periodontics Restorative Dent (2008) 0.91
Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett (2009) 0.89
Comparison of mineralized cancellous bone allograft (Puros) and anorganic bovine bone matrix (Bio-Oss) for sinus augmentation: histomorphometry at 26 to 32 weeks after grafting. Int J Periodontics Restorative Dent (2006) 0.88
Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer. Clin Cancer Res (2007) 0.88
Tracking immune cell proliferation and cytotoxic potential using flow cytometry. Methods Mol Biol (2011) 0.88
Multiparameter precursor analysis of T-cell responses to antigen. J Immunol Methods (2003) 0.87
Been there, not done that--melanoma in the age of molecular therapy. N Engl J Med (2011) 0.87
Self-recognition and tumor response to immunotherapy. J Clin Oncol (2005) 0.87
Primary melanoma of the spinal cord: a case report, molecular footprint, and review of the literature. J Clin Oncol (2011) 0.87
Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine. PLoS One (2012) 0.86
Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med (2007) 0.86
Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890). Med Oncol (2003) 0.86
Flow cytometry and gene expression profiling of immune cells of the carotid plaque and peripheral blood. Atherosclerosis (2013) 0.86
Long-term implant survival in the grafted maxillary sinus: a systematic review. Int J Periodontics Restorative Dent (2013) 0.85
Modulation of antitumor immune responses by hematopoietic cytokines. Cancer (2003) 0.85
Program to support safe administration of oral chemotherapy. J Oncol Pract (2006) 0.85
Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell Melanoma Res (2014) 0.85
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother (2005) 0.84
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma. Clin Genitourin Cancer (2007) 0.84
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients. Clin Immunol (2005) 0.84
CellVue Claret, a new far-red dye, facilitates polychromatic assessment of immune cell proliferation. Immunol Invest (2007) 0.83
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF). Prostate (2006) 0.83
Novel lipophilic tracking dyes for monitoring cell proliferation. Immunol Invest (2007) 0.83
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs (2013) 0.82
The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells. Transfusion (2014) 0.82
Optimized staining and proliferation modeling methods for cell division monitoring using cell tracking dyes. J Vis Exp (2012) 0.81
Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control (2002) 0.81
Maxillary sinus augmentation using recombinant bone morphogenetic protein-2/acellular collagen sponge in combination with a mineralized bone replacement graft: a report of three cases. Int J Periodontics Restorative Dent (2010) 0.81
Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy. PLoS One (2012) 0.81
Merkel cell polyomavirus and extrapulmonary small cell carcinoma. Oncol Lett (2013) 0.80
Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol (2010) 0.79
Adoptive cellular therapy using cells enriched for NKG2D+CD3+CD8+T cells after autologous transplantation for myeloma. Biol Blood Marrow Transplant (2012) 0.79
Immune mobilization of autologous blood progenitor cells: direct influence on the cellular subsets collected. Cytotherapy (2010) 0.79
Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods (2002) 0.79
Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials. Immunol Invest (2007) 0.79
Effect of xenograft (ABBM) particle size on vital bone formation following maxillary sinus augmentation: a multicenter, randomized, controlled, clinical histomorphometric trial. Int J Periodontics Restorative Dent (2013) 0.78
The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. Melanoma Res (2016) 0.77
Is pediatric melanoma always malignant? Cancer (2013) 0.77